Cargando…

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

Novel drugs like Abiraterone or Enzalutamide, which target androgen receptor (AR) signaling to improve androgen deprivation therapy (ADT), have been developed during the past years. However, the application of these drugs is limited because of occurrence of inherent or acquired therapy resistances d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puhr, M, Hoefer, J, Eigentler, A, Dietrich, D, van Leenders, G, Uhl, B, Hoogland, M, Handle, F, Schlick, B, Neuwirt, H, Sailer, V, Kristiansen, G, Klocker, H, Culig, Z
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865476/ https://www.ncbi.nlm.nih.gov/pubmed/26257066 http://dx.doi.org/10.1038/onc.2015.292

Ejemplares similares

PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
por: Puhr, Martin, et al.
Publicado: (2014)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer
por: Puhr, Martin, et al.
Publicado: (2021)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

The decay of $^{31}$Ar
por: García-Borge, M J, et al.
Publicado: (1990)

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

Study of bunch by bunch feedback system in TRISTAN-AR
por: Tobiyama, M, et al.
Publicado: (1998)

Decay of $^{46}$Ar
por: Huck, A, et al.
Publicado: (1978)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
por: Hoefer, Julia, et al.
Publicado: (2014)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

$\beta$ decay of $^{31}$Ar
por: Axelsson, L, et al.
Publicado: (1998)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016)

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
por: Handle, Florian, et al.
Publicado: (2019)

Determination of the spin of $^{31}$Ar
por: Thaysen, J, et al.
Publicado: (1999)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Umachigi, V. S.
Publicado: (1930)

Ars Longa
Publicado: (1893)

Boutique neutrons advance (40)Ar/(39)Ar geochronology
por: Rutte, Daniel, et al.
Publicado: (2019)

Regulation of AR mRNA translation in response to acute AR pathway inhibition
por: Somasekharan, Syam Prakash, et al.
Publicado: (2021)

Investigation of the $^{37}$Ar(n , p) $^{37}\!$Cl, $^{37}$Ar(n , $\alpha)^{34}\!$S and $^{39}$Ar(n , $\alpha) ^{36}$S reactions at various stellar temperatures
por: Goeminne, G, et al.
Publicado: (2001)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

The ArDM experiment
por: Haranczyk, M, et al.
Publicado: (2010)

C3aR and C5aR1 act as key regulators of human and mouse β-cell function
por: Atanes, Patricio, et al.
Publicado: (2017)

Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity
por: Hornig, N. C., et al.
Publicado: (2016)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Levels in $^{43}$K and $^{44}$K excited by the $\beta$-decay of $^{43}$Ar and $^{44}$Ar
por: Huck, A, et al.
Publicado: (1978)

Multi-particle emission in the decay of $^{31}$Ar
por: Koldste, G.T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qrgchhhag5fk500h2cn9macgam